BALLAD Belgium - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. The Belgian component of the Global Ballad pooled data analysis.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518349-85-01

Acronym

Ballad Belgium

Enrollment

Registered

2024-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small bowel adenocarcinoma

Brief summary

Disease free survival (defined as time from randomisation to recurrence, development of new primary or death from any cause).

Detailed description

Overall survival, toxicity, clinico-pathological, epidemiological and molecular profiling of SBA.

Interventions

DRUGFluorouracil Accord Healthcare 50 mg/ml

DRUGsolution pour injection ou perfusion

DRUGELVORINE 50 mg/5 mL

DRUGsolution injectable

DRUGELOXATIN 5 mg/ml concentraat voor oplossing voor infusie

DRUGXeloda 150 mg film-coated tablets

DRUGFluorouracil Accord Healthcare 50 mg/ml oplossing voor injectie of infusie

DRUGXeloda 500 mg film-coated tablets

DRUGELVORINE 25 mg/2

DRUG5 mL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease free survival (defined as time from randomisation to recurrence, development of new primary or death from any cause).	—

Secondary

Measure	Time frame
Overall survival, toxicity, clinico-pathological, epidemiological and molecular profiling of SBA.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026